Bio-Rad Laboratories, Inc.
BIO.B Healthcare Medical Devices
Bio-Rad Laboratories, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $2.6 billion, up 0.65% from fiscal 2024.
- Revenue
- +0.52%
- EPS
- +234.9%
- Free cash flow
- +8.07%
- Total debt
- +0.11%
Quarter to September 2026, against a year earlier
Follow BIO.B
Alert me
Bio-Rad Laboratories, Inc. (BIO.B) P/B ratio
As of 27 October 2026, Bio-Rad Laboratories, Inc. (BIO.B) trades at a P/B ratio of 1.3×. Over the past ten years it has ranged from 0.9× (May 2024) to 2.7× (March 2018); the current reading is higher than 27% of that period. That is below the Medical Devices industry median of 2.5× and below the Healthcare sector median of 2.3×.
P/B ratio, daily
Embed this chart
Annual newest first
| Period | P/B ratio | Change |
|---|---|---|
| FY2025 | 1.1× | (18.74%) |
| FY2024 | 1.4× | 30.51% |
| FY2023 | 1.1× | (14.52%) |
| FY2022 | 1.3× | (20.45%) |
| FY2021 | 1.6× | (8.91%) |
| FY2020 | 1.7× | (9.74%) |
| FY2019 | 1.9× | 12.29% |
| FY2018 | 1.7× | (29.21%) |
| FY2017 | 2.4× | 15.34% |
| FY2016 | 2.1× | 29.57% |
Quarterly newest first
| Period | P/B ratio | Change |
|---|---|---|
| Sep 2026 | 1.3× | 16.33% |
| Jun 2026 | 1.1× | 0.97% |
| Mar 2026 | 1.1× | (3.66%) |
| Dec 2025 | 1.1× | (0.18%) |
| 43 more quarters | Free account |
Against its own ten years
P/B ratio against peers
| Company | P/B ratio |
|---|---|
| BIO Bio-Rad Laboratories, Inc. compare | 1.3× |
| BIO.B Bio-Rad Laboratories, Inc. | 1.3× |
| GMED Globus Medical, Inc. compare | 2.3× |
| SNN Smith & Nephew SNATS, Inc. compare | 2.8× |
| BRKR Bruker Corporation compare | 3.7× |
| PODD Insulet Corporation compare | 7.6× |
| PEN Penumbra, Inc. compare | 8.0× |
| TXG 10x Genomics compare | 9.2× |
| GKOS Glaukos Corporation compare | 18.1× |
| Medical Devices industry median | 2.5× |
| Healthcare sector median | 2.3× |
| Market median | 1.7× |
What P/B ratio is
Price to Book Value tells an investor how much the market pays for a company’s shares relative to the accounting net worth that belongs to common shareholders.
Stock Price ÷ (Common Equity (Total) (latest quarter) ÷ Shares (Basic, Weighted) (latest quarter))
More on BIO.B
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement